US FDA approves new therapy for myelodysplastic syndromes a rare form of blood cancers

The US FDA granted the approval of Tibsovo to Servier Pharmaceuticals LLC and RealTime IDH1 Assay to Abbott Laboratories. MDS are a rare form of blood cancers that can occur when the mutations in the bone marrow progenitor cells (cells that form blood) lead to insufficient numbers of healthy blood cells.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/5GcgOFE
via